Schizoaffective Disorders Completed Phase 4 Trials for Ziprasidone (DB00246)

Also known as: Schizoaffective disorder / Schizophrenia schizoaffective / Schizoaffective psychosis / Schizo-affective type schizophrenia

IndicationStatusPhase
DBCOND0033299 (Schizoaffective Disorders)Completed4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02307396Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic PatientsTreatment
NCT00330863Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating EfficacyTreatment
NCT00034801Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With SchizophreniaTreatment
NCT00406315Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To ZiprasidoneTreatment
NCT00458211Efficacy and Tolerability of Switching to Ziprasidone From Other AntipsychoticsTreatment
NCT00649064A Study of the Effects of Ziprasidone for the Treatment of Schizophrenia or Schizoaffective Disorder in Patients Who Were Switched From Other Antipsychotic DrugsTreatment
NCT00650429A Study of the Efficacy and Safety of Ziprasidone for the Treatment of Acute Exacerbation of Schizophrenia or Schizoaffective DisorderTreatment
NCT01198353Effectiveness of Ziprasidone for Patients With SchizophreniaTreatment